Fibrinogen as risk factor;El fibrinógeno como factor de riesgo cardiovascular

Archivos de Cardiologia de Mexico

Volumn 73, Issue 1, 2003, Pages 7-10

  Izaguirre Ávila, Raúl ^a   Zaldívar Alcántara, Helena ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Atherothrombosis; Coronary artery disease; Fibrinogen

Indexed keywords

FIBRINOGEN;

ARTERY THROMBOSIS; BLOOD CLOTTING; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; EDITORIAL; HUMAN;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FIBRINOGEN; HUMANS; RISK FACTORS;

EID: 0037266621     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (36)

1. Green FR: Fibrinogen polymorphisms and atherothrombotic disease. Ann NY Acad Sci 2001; 936: 549-559.
2. THOMAS AE, GREEN FR, KELLEHER CH, WILKESB HC, BRENNAN PJ, MEADE TW, ET AL: Variation in the promoter region of the beta fibrinogen gene is associated with plasma fibrinogen levels in smokers and no-smokers. Thromb Haemost 1991; 65: 487-490.
3. IACOVIELLO L, VISCHETTI M, ZITO F, BENEDETTA M: Genes encoding fibrinogen and cardiovascular risk. Hypertension 2001; 38: 1199-1203.
4. HUMPHRIES SE, LOUNG LA, MONTGOMERY HE, DAY I, MOHAMED V, YUDKIN J: Gene-environment interaction in the determinations of levels of plasma fibrinogen. Thromb Haemost 1999; 82: 818-825.
5. BASSO F, LOWE GD, RUMLEY A, MCMAHON AD, HUMPHRIES SE: Interleukin-6-174G > C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22: 599-604.
6. FENF D, LINDPAINTNER K, LARSON MG, O'DONNELL CJ, LIPINSKA I, SUTHERLAND PA, ET AL: Platelet gycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: the Framingham Heart Stuply. Circulation 2001; 104: 140-144.
7. IZAGUIRRE R, RUIZ DE CHÁVEZ A, VILLAVICENCIO R, GOMEZ A, MAR R, SPÍNDOLA C, CASANOVA J: Variaciones en la hemostasia y fibrinólisis durante el tratamiento del infarto agudo del miocardio con activador tisular del plasminógeno. Arch Inst Cardiol Mex 1993; 63: 235-240.
8. GOLD HK, LEINBACH RC, GARABEDIAN HD, YASUDA T, JOHNS JA, GROSSBARD EB, ET AL: Acute coronary reocclusion after thrombolysis with recombinant tissue-type plasminogen activator. Prevention by maintenance infusion. Circulation 1986; 73: 347-352.
9. SMITH E, KEEN GA, GRANT A: Fate of fibrinogen in human arterial intima. Arteriosclerosis 1990; 10: 263-275.
10. OTTO C, RICHTER WO, SCHWANDT P: Contribution of fibrinogen and lipoproteins to plasma viscosity in hypercholesterolemia and hypertriglyceridemia: evaluation by selective depletion of low density lipoproteins or fibrinogen. Metabolism 2000; 49: 810-813.
11. TATARU MC, SCHULTE H, VON ECKARDSTEIN A, HEINRICH J, ASSMANN G, KOEHLER E: Plasmafibrinogen in relation to the severity of arteriosclerosis in patients with stable angina pectoris after myocardial infarction. Coron Artery Dis 2001; 12: 157-165.
12. LOWE GD, FOWKES FG, DAWES J, DONNAN PT, LENNIE SE, HOUSLEY E: Blood viscosity, fibrinogen and activation of coagulation and leukocytes in peripheal arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87: 1915-1920.
13. MONTALESCOT G, COLLET JP, CHOUSSAT R, THOMAS D: Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998; 19: H11-H17.
14. WILHEMSEN L, SVARDSUDD K, KORSAN K, LARSSON B, WELIN L, TIBBLIN G: Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505.
15. QIZILBASH N, JONES L, WARLOW C, MANN J: Fibrinogen and lipid concentrations as risk factors for transient ischaemic attacks and minor ischaemic strokes. Br J Med L 1991; 303: 605-609.
16. BAINTON D, SWEETNAM P, BAKER I, ELWOOD P: Peripheal vascular disease. Consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study. Br Heart J 1994; 72: 128-132.
17. COLAS JL, MONTALESCOT G, TRIBOUILLOY C: Fibrinogen: a cardiovascular risk factor. Presse Med 2000; 29: 1862-1866.
18. MEADE TW, NORTH WR, CHAKRABARTI R, STIRLING Y, HAINES AP, THOMPSON SG, ET AL: Haemostatic function and cardiovascular death: Early results ofa Prospective study. Lancet 1980; 1: 1050-1054.
19. MEADE TW, MELLOWS S, BROZOVIC M, MILLER GJ, CHAKRABARTI RR, NORTH WR, ET AL: Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-537.
20. ERNST E, RESCH K: Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.
21. DANESH J, COLLINS R, APPLEBY P, PETO R: Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective sudies of coronary heart disease. JAMA 1998; 279: 1477-1482.
22. MARESCA G, DI BLASIO A, MARCHILI R, DI MINNO G: Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.
23. ACEVEDO M, FOODY JM, PEARCE GL, SPRECHER DL: Fibrinogen: associations with cardiovascular events in an outpatient clinic. Am Heart J 2002; 143: 277-282.
24. IZAGUIRRE R, DE LA PEÑA A, BARINAGARREMENTERÍA F, GONZÁLEZ H, RAMÍREZ AE, RUIZ JL, ET AL: Effect of clopidogrel on platelet aggregation and plasma concentration of fibrinogen in subjects with cerebral or coronary atherosclerotic disease. Clin Appl Thromb Hemost 2002; 8: 1169-177.
25. MA J, HENNEKENS C, RIDKER P, STUMPFER M. A Prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 1999; 33: 1347-1352.
26. ROETERS JE, WESTERVELD HT, ERKELENS DW, VAN DER WALL E: Risk factors for coronary heart disease: implications of gender. Cardiovascular Res 2002; 53: 538-549.
27. WANNAMETHEE SG, LOWE GD, WHINCUP PH, RUMLEY A, WALKER M, LENNON L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002; 105: 1785-1790.
28. KANNEL WB, DÁGOSTINO RB, BELANGER AJ: Fibrinogen, cigarrete smoking and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987; 113: 1006-1010.
29. CANTIN B, DESPRES JP, LAMARCHE B, MOORJANI S, LUPIEN PJ, BOGATY P, ET AL: Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol 2002; 89: 662-666.
30. STOUT RW, CRAWFORD V: Seasonal variations in fibrinogen concentrations among elderly people. Lancet 1991; 339: 9-13.
31. WOODHOUSE PR, KHAW KT, PLUMMER M, FOLEY A, MEADE TW: Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 1994; 343: 345-349.
32. VAN DEL BOM J, DE MAAT M, BOTS M, HOFMAN A, KLUYFT C, GROBEE D: Seasonal variation in fibrinogen in the Rotterdam study. Throm Haemost 1997; 78: 1059-1062.
33. ROSENSON RS, MOSCA L, STAFFILENO BA, TANGNEY CC: Variability in fibrinogen measurements: an obstacle to cardiovascular risk stratification. Atherosclerosis 2001; 159: 225-230.
34. FOLSOM A, Wu K, ROSAMOND W, SHARRET A, CHAMBLESS L: Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997; 96: 1102-1108.
35. CHANDLER W, RODGERS GM, SPROUSE JT, THOMPSON AR: Elevated hemostatic factor levels as potential risk factors for thrombosis. Arch Pathol Lab Med 2002; 126: 1405-1414.
36. STEC J, SILBERSHATZ H, TOFLER G, MATHENEY T, SUTHERLAND P, PIPINSKA I, ET AL: Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham offspring population. Circulation 2000; 102: 1634-1638.